The global inflammatory bowel disease treatment market size is
expected to reach USD 22.4 billion by 2026, according to a new report by Grand
View Research, Inc., registering a 4.4% CAGR during the forecast period.
Increasing prevalence and incidence of Crohn’s disease and ulcerative colitis
is one of the major factors contributing to the market.
According to a study published in the NCBI in 2019, the North
America incidence of inflammatory bowel disease (IBD) treatment is around 2.2
to 19.2 cases per 100,000 persons per year. It was also published that around
238 per 100,000 population in U.S. were suffering from ulcerative colitis.
Furthermore, The Centers for Disease Control and Prevention (CDC) estimates
that in U.S., every year nearly 1-1.3 million people suffer from inflammatory
bowel disease.
In addition, involvement of regulatory bodies for funding and
designation is expected to propel the growth of the market. For instance, the
Crohn’s and Colitis Foundation offers grants and fellowships for research on
inflammatory bowel disease (includes Crohn’s disease and ulcerative colitis).
Growing geriatric population is expected to positively impact the
overall market. According to an article published in 2018 in the United States
Census Bureau, it is estimated that by 2035, the population aged 65 years and
above is expected to reach 78 million, whereas children under the age of 18
might be around 76.7million.
Moreover, companies such as Johnson & Johnson Services Inc.;
Pfizer Inc.; Takeda Pharmaceutical Company Limited; and AbbVie Inc. are majorly
involved in product research and development and this is also considered as one
of the major driving factors for the market.
Browse full research report on Inflammatory Bowel Disease
Treatment Market: https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market
Further key findings from the report suggest:
- The
global inflammatory bowel disease treatment market is anticipated to reach
USD 22.4 billion by 2026, exhibiting a CAGR of 4.4% from 2018 to 2026
- Crohn’s
disease dominated the market by type in 2018 due to increasing incidence
of the disease. On the other hand, ulcerative colitis was estimated to be
the fastest growing segment owing to presence of strong pipeline products
for its treatment
- By
route of administration, injectables dominated the IBD treatment market in
2018 while oral was estimated to be the fastest growing segment over the
forecast period
- Aminosalicylic
acid (ASAs) was considered to be the largest oral segment in 2018 and JAK
inhibitors to be the fastest growing segment
- In
2018, TNF-inhibitors dominated the injectables segment while anti-integrins
are estimated to be the fastest growing segment
- Hospital
pharmacy was the largest segment in 2018 with a market share of 36.6% and
online pharmacy was anticipated to be the fastest owing to the comfort,
flexibility and convenience provided
- North
America held the dominant share in 2018 owing to presence of key companies
in this region. Asia Pacific, on the other hand, was estimated to be the
fastest growing region
- Some
of the key companies operating in this market are Johnson & Johnson
Services Inc.; Pfizer Inc.; Takeda Pharmaceutical Company Limited; AbbVie
Inc.; Celltrion Healthcare Co., Ltd.; CELGENE CORPORATION; COSMO
PHARMACEUTICALS; Innovate Biopharmaceuticals; UCB S.A.; and Gilead
Sciences.
Browse
request sample of this report by Grand View Research: https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market/request/rs1
Grand View Research has segmented the global inflammatory bowel
disease treatment market based on type, route of administration, distribution
channel, and region:
IBD Treatment Type Form Outlook (Revenue, USD Million, 2014 - 2026
- Crohn’s
disease
- Ulcerative
colitis
IBD Treatment Route of Administration Outlook (Revenue, USD
Million, 2014 - 2026)
- Injectables
- TNF-inhibitors
- IL
inhibitors
- Anti-integrin
- Others
- Oral
- ASAs
- Corticosteroids
- JAK
inhibitors
- Others
IBD Treatment Distribution Channel Outlook (Revenue, USD Million,
2014 - 2026)
- Hospital
Pharmacy
- Retail
Pharmacy
- Online
Pharmacy
IBD Treatment Regional Outlook (Revenue, USD Million, 2014 - 2026)
- North
America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Asia
Pacific
- Japan
- China
- India
- South
Korea
- Australia
- Singapore
- Latin
America
- Brazil
- Mexico
- Argentina
- Middle
East & Africa
- South
Africa
- UAE
- Saudi
Arabia
About
Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, we offer market intelligence studies
ensuring relevant and fact-based research across a range of industries, from
technology to chemicals, materials and healthcare.
For
more info visit @ https://www.grandviewresearch.com
No comments:
Post a Comment